Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix announced key updates as of October 31, 2022. The company has 34,875,872 outstanding shares and a total of 36,286,313 theoretical voting rights. The exercisable voting rights amounted to 36,273,212. The firm focuses on innovative therapeutic solutions for cancer treatment, particularly through its lead product NBTXR3, designed to enhance tumor control. These developments underline Nanobiotix's commitment to improving patient outcomes in oncology.
Nanobiotix announced the formation of a Scientific Advisory Board comprising twelve expert oncologists from the US and Europe to support the development of its lead therapeutic candidate, NBTXR3. The board's diverse expertise aims to enhance clinical trial strategies and improve patient care. Leonard Farber, MD, highlighted the necessity of multidisciplinary knowledge for advancing this innovative cancer treatment. NBTXR3 targets solid tumors, with an emphasis on head and neck cancers, leveraging a novel physics-based approach.
Nanobiotix, a late-stage clinical biotechnology company, announced participation in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2022. Laurent Levy, co-founder and chairman, along with Bart Van Rhijn, CFO, will speak at 5:00 PM GMT/12:00 PM ET. The event will be webcast live and available for replay for 30 days. The company is focused on innovative physics-based therapies, including NBTXR3, to improve treatment outcomes in cancer patients, particularly those with head and neck cancers.
Nanobiotix will release its financial results for Q3 2022 on November 9, 2022, after US market close. A conference call is scheduled for November 10, 2022, at 8:00 AM ET, where CEO Laurent Levy and CFO Bart Van Rhijn will discuss the results and company updates. The call will be accessible via the company's website, allowing participants to register in advance. Nanobiotix focuses on innovative cancer therapies, particularly through its lead product, radiotherapy-activated NBTXR3, targeting solid tumors.
Nanobiotix (NASDAQ: NBTX) has signed a final restructuring agreement with the European Investment Bank (EIB) to realign approximately €30.7 million in debt obligations with its commercialization timelines. The agreement allows deferral of €25.3 million in principal repayments until June 2029 and restructures €5.4 million in accrued interest as payment-in-kind until October 2024. Additionally, a new €20 million milestone payment is set for June 2029, contingent on commercial success. This restructuring aims to support the anticipated revenue generation from the company’s lead product, NBTXR3, in cancer treatment.
Nanobiotix reported updated information regarding its outstanding shares and voting rights as of September 30, 2022. Currently, there are 34,875,872 shares outstanding, with a total of 36,277,898 theoretical voting rights and 36,261,825 exercisable voting rights. This data is crucial for ensuring transparency for shareholders and aligns with the French regulatory requirements.
Nanobiotix announced operational progress in its pivotal Phase 3 study, NANORAY-312, focusing on elderly patients with locally advanced head and neck cancer. The first patient has been enrolled in Asia, with plans to recruit approximately 100 patients globally. Financially, the company reported €63 million in cash equivalents as of June 30, 2022, and expects funding through Q1 2024 due to a debt restructuring with the EIB. Despite a stable revenue of €1.3 million, R&D expenses rose to €16.6 million. The net loss decreased to €26.4 million, or €0.76 per share, compared to €30.4 million in 2021.
Nanobiotix plans to report its financial results for the half-year ending June 30, 2022, on September 28, 2022, after U.S. market close. A conference call and live audio webcast will follow on September 29, 2022, at 8:00 AM ET / 2:00 PM CET. The call will feature CEO Laurent Levy and CFO Bart Van Rhijn, discussing results and business updates. Interested participants can access the live webcast on the company’s website.
Nanobiotix (NASDAQ: NBTX) announced the recommended phase 2 dose for NBTXR3, which is set at 33% of gross tumor volume in three cohorts for treating head and neck squamous cell carcinoma (HNSCC). The company expects to submit a Phase 3 trial protocol to the FDA by Q1 2023, with updated clinical data from Study 1100 anticipated in Q4 2022. The ongoing study aims to evaluate NBTXR3 in combination with anti-PD-1 therapies for patients with recurrent or metastatic HNSCC, including those resistant to previous immunotherapy.
Nanobiotix reached an agreement to restructure €30.7 million in debt obligations from its 2018 loan with the European Investment Bank (EIB). This restructuring aims to align debt with development timelines, extending the maturity dates to June 2029 for principal repayments and October 2024 for interest payments. This extension will enhance Nanobiotix's operational runway into early 2024, allowing focus on lead programs for its cancer treatment, NBTXR3. Execution of the amendment is expected in Q4 2022, contingent on final legal documentation.